B. Riley analyst Mayank Mamtani raised the firm’s price target on Trevi Therapeutics (TRVI) to $20 from $11 and keeps a Buy rating on the shares. The recent overwhelmingly positive Phase IIa RIVER refractory chronic cough data-specific insights informative of further de-risking of the Phase IIb IPF CC CORAL study readout anticipated in Q2, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Trevi Therapeutics’ Promising Prospects: Buy Rating Backed by Positive Trial Results and Market Potential
- Trevi Therapeutics’ Haduvio: Promising Developments and Strategic Advancements Reinforce Buy Rating
- Trevi Therapeutics: Buy Rating Backed by Promising Haduvio Trial Results and Strong Market Potential
- Trevi Therapeutics Advances Haduvio in Clinical Trials
- Trevi Therapeutics reports Q4 EPS (11c), consensus (12c)
Questions or Comments about the article? Write to editor@tipranks.com